Harm-to-Benefit Ratio of Fecal Immunochemical Test–Based Screening for Colorectal Cancer Given Prior Fecal Hemoglobin Concentrations
The harm-to-benefit ratio of FIT-based screening is substantially greater in individuals without vs with prior detectable f-Hb. Less intensive screening should be considered for this lower-risk group.
Authors
- Esther Toes‐Zoutendijk (ORCID: https://orcid.org/0000-0003-4001-2949)
- Manon C.W. Spaander (ORCID: https://orcid.org/0000-0002-9103-9757)
- Reinier G.S. Meester (ORCID: https://orcid.org/0000-0003-4645-1221)
- Lucie de Jonge (ORCID: https://orcid.org/0000-0001-5718-1058)
- Evelien Dekker (ORCID: https://orcid.org/0000-0002-4363-0745)
- Folkert J. van Kemenade (ORCID: https://orcid.org/0000-0002-4225-4354)
- Irıs D. Nagtegaal (ORCID: https://orcid.org/0000-0003-0887-4127)
- Maria Katsara
- Monique Esther van Leerdam (ORCID: https://orcid.org/0000-0002-5719-3208)
- Hilliene J. van de Schootbrugge‐Vandermeer (ORCID: https://orcid.org/0000-0002-0543-4225)
- Anneke J. van Vuuren (ORCID: https://orcid.org/0000-0002-0624-3623)
- Iris Lansdorp‐Vogelaar
Institutions
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- Amsterdam UMC Location University of Amsterdam (NL)
- Radboud University Medical Center (NL)
- Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL)
- University of Amsterdam (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Clinical Gastroenterology and Hepatology
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1016/j.cgh.2024.08.041
- Citations
- 4
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 1.56
Funders
- Rijksinstituut voor Volksgezondheid en Milieu